Aluminum toxicity

Background

Aluminum Metal

• Dusts cause respiratory tract and eye irritation
• Acute exposures can cause bronchoconstriction and asthma-like response
• Chronic exposure can lead to pulmonary fibrosis
• Increased incidence of cancer

Aluminum phosphide

• Used as a fumigant
• Contact with moisture produces phosphine gas
• Respiratory tract irritant

Aluminum oxide

• Physical irritant, nuisance particulate

Systemic aluminum toxicity

• Usually in renal patients on long-term dialysis with aluminum-containing dialysate
• Rarely acute
• Muscle weakness (especially proximal)
• Premature osteoporosis, bone pain, multiple fractures
• Seziures
• Acute or subacute altered mental status

Differential Diagnosis

Heavy metal toxicities

• Aluminum toxicity
• Antimony toxicity
• Arsenic toxicity
• Barium toxicity
• Beryllium toxicity
• Bismuth toxicity
• Boron toxicity
• Cadmium toxicity
• Cesium toxicity
• Chromium toxicity
• Cobalt toxicity
• Copper toxicity
• Gold toxicity
• Iron toxicity
• Lead toxicity
• Lithium toxicity
• Manganese toxicity
• Mercury toxicity
• Nickel toxicity
• Phosphorus toxicity
• Platinum toxicity
• Selenium toxicity
• Silver toxicity
• Thallium toxicity
• Tin toxicity
• Vanadium toxicity
• Zinc toxicity

Evaluation

• Aluminum level > 50 µg/L (mcg/dL) suggests aluminum overload and possible toxicity
  • Symptomatic patients with levels 20-50 may also need treatment

Management

• Stop exposure
• Supportive care is the cornerstone of treatment, particularly in mild cases. This includes respiratory support (e.g., bronchodilators for bronchospasm) and symptomatic treatment of neurological or musculoskeletal manifestations.
• Chelation therapy:
  • Deferoxamine is the chelator of choice for aluminum toxicity. It binds free aluminum, forming a water-soluble complex (aluminoxamine) excreted by the kidneys.
  • Indications include: symptomatic patients with serum aluminum >50 µg/L, or any patient with encephalopathy, bone disease, or anemia attributed to aluminum.
  • Use with caution in patients with renal impairment, as deferoxamine-aluminum complexes require adequate renal clearance; dialysis may be needed to remove the chelated complex.
• Dialysis: Consider hemodialysis in patients with renal failure and aluminum overload, particularly if encephalopathy is present or if chelation is being performed.
• Avoidance of aluminum-containing medications, including phosphate binders, IV fluids, or antacids, is important during and after treatment.

Disposition

Admission Criteria

• Symptomatic patients (e.g., altered mental status, seizures, severe bone pain).
• Known or suspected aluminum overload in the setting of renal failure.
• Patients requiring chelation or dialysis should be admitted for monitoring and treatment.

Outpatient Management

• Asymptomatic patients with mild elevations (e.g., <50 µg/L) and no risk factors (e.g., normal renal function) may be monitored closely with repeat labs and exposure cessation.

Follow-up

• Patients with chronic exposure or prior toxicity should be referred for occupational medicine or toxicology evaluation.
• Renal patients should have their dialysis fluids and medications reviewed for aluminum content.
• Bone health monitoring may be warranted in those with chronic exposure or symptoms suggestive of osteomalacia or osteoporosis.

See Also

• Toxicology (main)